Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.

Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, Xu M, Bleeker FE, Wilmink JW, Carraway HE, Mukherjee S, Sekeres MA, van Noorden CJF, Maciejewski JP.

Clin Cancer Res. 2018 Apr 1;24(7):1705-1715. doi: 10.1158/1078-0432.CCR-17-2796. Epub 2018 Jan 16.

PMID:
29339439
2.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2017 Dec 18:JCO2017750232. doi: 10.1200/JCO.2017.75.0232. [Epub ahead of print]

PMID:
29252123
3.

Rational management approach to pure red cell aplasia.

Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, Maciejewski JP.

Haematologica. 2018 Feb;103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7.

4.

RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013.

Molenaar RJ, Radivoyevitch T, Wilmink JW.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx103. No abstract available.

PMID:
29117390
5.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S.

Leukemia. 2018 Apr;32(4):952-959. doi: 10.1038/leu.2017.323. Epub 2017 Nov 6.

PMID:
29104287
6.

A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia.

Sakai H, Hosono N, Nakazawa H, Przychodzen B, Polprasert C, Carraway HE, Sekeres MA, Radivoyevitch T, Yoshida K, Sanada M, Yoshizato T, Kataoka K, Nakagawa MM, Ueno H, Nannya Y, Kon A, Shiozawa Y, Takeda J, Shiraishi Y, Chiba K, Miyano S, Singh J, Padgett RA, Ogawa S, Maciejewski JP, Makishima H.

Leukemia. 2018 Mar;32(3):839-843. doi: 10.1038/leu.2017.319. Epub 2017 Nov 3. No abstract available.

PMID:
29099495
7.

Long-Term Deficits in Behavior Performances Caused by Low- and High-Linear Energy Transfer Radiation.

Patel R, Arakawa H, Radivoyevitch T, Gerson SL, Welford SM.

Radiat Res. 2017 Dec;188(6):672-680. doi: 10.1667/RR14795.1. Epub 2017 Sep 29.

PMID:
28961076
8.

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, Maciejewski JP.

Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22. No abstract available.

PMID:
28935992
9.

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.

PLoS Med. 2017 Sep 7;14(9):e1002382. doi: 10.1371/journal.pmed.1002382. eCollection 2017 Sep.

10.

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18. No abstract available.

PMID:
28819282
11.

The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy.

Bat T, Abdelhamid ON, Balasubramanian SK, Mai A, Radivoyevitch T, Clemente M, Maciejewski JP.

Br J Haematol. 2017 Aug 14. doi: 10.1111/bjh.14862. [Epub ahead of print] No abstract available.

PMID:
28804905
12.

Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.

Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):857-862. doi: 10.1016/j.clml.2017.07.003. Epub 2017 Jul 14. Review.

PMID:
28778620
13.

GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition.

Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, Maciejewski J, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Saunthararajah Y.

J Clin Invest. 2017 Sep 1;127(9):3527-3542. doi: 10.1172/JCI93488. Epub 2017 Jul 31.

14.

Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).

Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG 2nd, Jerez A, Thota S, Patel B, Hirsch C, Nazha A, Desamito J, Lichtin A, Pohlman B, Sekeres MA, Radivoyevitch T, Maciejewski JP.

Leuk Lymphoma. 2018 Feb;59(2):416-422. doi: 10.1080/10428194.2017.1339880. Epub 2017 Jun 20.

PMID:
28633612
15.

Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer.

Velcheti V, Radivoyevitch T, Saunthararajah Y.

Am Soc Clin Oncol Educ Book. 2017;37:812-824. doi: 10.14694/EDBK_174175. Review.

16.

Genomic determinants of chronic myelomonocytic leukemia.

Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, Maciejewski JP.

Leukemia. 2017 Dec;31(12):2815-2823. doi: 10.1038/leu.2017.164. Epub 2017 May 30.

PMID:
28555081
17.

Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.

Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, Nazha A, Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips BL, Huang S, Wang J, He C, Li GM, Radivoyevitch T, Aifantis I, Maciejewski JP, Yang FC, Jin P, Xu M.

Nat Commun. 2017 Apr 25;8:15102. doi: 10.1038/ncomms15102.

18.

Molecular features of early onset adult myelodysplastic syndrome.

Hirsch CM, Przychodzen BP, Radivoyevitch T, Patel B, Thota S, Clemente MJ, Nagata Y, LaFramboise T, Carraway HE, Nazha A, Sekeres MA, Makishima H, Maciejewski JP.

Haematologica. 2017 Jun;102(6):1028-1034. doi: 10.3324/haematol.2016.159772. Epub 2017 Mar 2.

19.

Dynamics of clonal evolution in myelodysplastic syndromes.

Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP.

Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.

PMID:
27992414
20.

The complexity of interpreting genomic data in patients with acute myeloid leukemia.

Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway HE, Hirsch CM, Przychodzen B, Patel BJ, Clemente M, Sanikommu SR, Kalaycio M, Maciejewski JP, Sekeres MA.

Blood Cancer J. 2016 Dec 16;6(12):e510. doi: 10.1038/bcj.2016.115.

21.

The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.

Statler A, Radivoyevitch T, Siebenaller C, Gerds AT, Kalaycio M, Kodish E, Mukherjee S, Cheng C, Sekeres MA.

Leukemia. 2017 Aug;31(8):1808-1815. doi: 10.1038/leu.2016.374. Epub 2016 Dec 7.

PMID:
27924815
22.

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2016 Nov;30(11):2214-2220. doi: 10.1038/leu.2016.138. Epub 2016 May 20.

PMID:
27311933
23.

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP.

Leukemia. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18. No abstract available.

24.

Inhibition of yeast ribonucleotide reductase by Sml1 depends on the allosteric state of the enzyme.

Misko TA, Wijerathna SR, Radivoyevitch T, Berdis AJ, Ahmad MF, Harris ME, Dealwis CG.

FEBS Lett. 2016 Jun;590(12):1704-12. doi: 10.1002/1873-3468.12207. Epub 2016 May 27.

25.

Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.

Jackson RC, Radivoyevitch T.

AAPS J. 2016 Jul;18(4):914-22. doi: 10.1208/s12248-016-9905-2. Epub 2016 Mar 23.

PMID:
27007600
26.

Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia.

Radivoyevitch T, Sachs RK, Gale RP, Smith MR, Hill BT.

Leuk Res. 2016 Apr;43:9-12. doi: 10.1016/j.leukres.2016.02.008. Epub 2016 Feb 21.

PMID:
26922774
27.

GFI1 as a novel prognostic and therapeutic factor for AML/MDS.

Hönes JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schütte J, Al-Matary YS, Lams RF, Fraszscak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceição Castro SV, Görgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G, Dührsen U, Maciejewski JP, Möröy T, Khandanpour C.

Leukemia. 2016 Jun;30(6):1237-45. doi: 10.1038/leu.2016.11. Epub 2016 Feb 5.

PMID:
26847026
28.

miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.

Al-Harbi S, Choudhary GS, Ebron JS, Hill BT, Vivekanathan N, Ting AH, Radivoyevitch T, Smith MR, Shukla GC, Almasan A.

Mol Cancer. 2015 Nov 4;14:185. doi: 10.1186/s12943-015-0460-8.

29.

Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, Kalaycio ME, Carraway HE, Mukherjee S, Sekeres MA, Maciejewski JP.

Leukemia. 2016 Feb;30(2):285-94. doi: 10.1038/leu.2015.258. Epub 2015 Sep 22.

PMID:
26460209
30.

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.

Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, Henneman P, Khurshed M, Lenting K, Mul AN, Dimitrakopoulou D, van Drunen CM, Hoebe RA, Radivoyevitch T, Wilmink JW, Maciejewski JP, Vandertop WP, Leenders WP, Bleeker FE, van Noorden CJ.

Cancer Res. 2015 Nov 15;75(22):4790-802. doi: 10.1158/0008-5472.CAN-14-3603. Epub 2015 Sep 11.

31.

Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes.

Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, Carew J, Makishima H, Sekeres MA, Maciejewski JP.

Haematologica. 2015 Nov;100(11):e434-7. doi: 10.3324/haematol.2015.130112. Epub 2015 Aug 13. No abstract available.

32.

BRCC3 mutations in myeloid neoplasms.

Huang D, Nagata Y, Grossmann V, Radivoyevitch T, Okuno Y, Nagae G, Hosono N, Schnittger S, Sanada M, Przychodzen B, Kon A, Polprasert C, Shen W, Clemente MJ, Phillips JG, Alpermann T, Yoshida K, Nadarajah N, Sekeres MA, Oakley K, Nguyen N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Miyano S, Haferlach C, Kern W, Haferlach T, Du Y, Ogawa S, Makishima H.

Haematologica. 2015 Aug;100(8):1051-7. doi: 10.3324/haematol.2014.111989. Epub 2015 May 22.

33.

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.

Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, Hirsh C, Viny AD, Hosano N, Bleeker FE, Meggendorfer M, Alpermann T, Shiraishi Y, Chiba K, Tanaka H, van Noorden CJ, Radivoyevitch T, Carraway HE, Makishima H, Miyano S, Sekeres MA, Ogawa S, Haferlach T, Maciejewski JP.

Leukemia. 2015 Nov;29(11):2134-42. doi: 10.1038/leu.2015.91. Epub 2015 Apr 3.

34.

Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example.

Radivoyevitch T, Siranart N, Hlatky L, Sachs R.

AAPS J. 2015 Mar;17(2):447-56. doi: 10.1208/s12248-014-9715-3. Epub 2015 Feb 7.

35.

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Husseinzadeh H, Przychodzen B, Rump M, Hobson S, Earl M, Sobecks R, Dean R, Reu F, Tiu R, Hamilton B, Copelan E, Lichtin A, Hsi E, Kalaycio M, Maciejewski J.

J Clin Invest. 2015 Mar 2;125(3):1043-55. doi: 10.1172/JCI78789. Epub 2015 Jan 26.

36.

Etiology and treatment of hematological neoplasms: stochastic mathematical models.

Radivoyevitch T, Li H, Sachs RK.

Adv Exp Med Biol. 2014;844:317-46. doi: 10.1007/978-1-4939-2095-2_16. Review.

PMID:
25480649
37.

Why is there so much therapy-related AML and MDS and so little therapy-related CML?

Gale RP, Hlatky L, Sachs RK, Radivoyevitch T.

Leuk Res. 2014 Oct;38(10):1162-4. doi: 10.1016/j.leukres.2014.08.002. Epub 2014 Aug 11. No abstract available.

PMID:
25175829
38.

A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.

Jackson RC, Radivoyevitch T.

Cancer Chemother Pharmacol. 2014 Oct;74(4):765-76. doi: 10.1007/s00280-014-2556-z. Epub 2014 Aug 9.

PMID:
25107570
39.

Genetic alterations of the cohesin complex genes in myeloid malignancies.

Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, Sekeres MA, Levine RL, Maciejewski JP.

Blood. 2014 Sep 11;124(11):1790-8. doi: 10.1182/blood-2014-04-567057. Epub 2014 Jul 8.

40.

Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system.

Collie AM, Nölling J, Divakar KM, Lin JJ, Carver P, Durkin LM, Hill BT, Smith MR, Radivoyevitch T, Kong LI, Daly T, Murugesan G, Guenther-Johnson J, Dave SS, Manilich EA, Hsi ED.

Br J Haematol. 2014 Oct;167(2):281-5. doi: 10.1111/bjh.12983. Epub 2014 Jun 25. No abstract available.

41.

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.

Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE.

Biochim Biophys Acta. 2014 Dec;1846(2):326-41. doi: 10.1016/j.bbcan.2014.05.004. Epub 2014 May 28. Review.

PMID:
24880135
42.
43.

Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Gu X, Hu Z, Ebrahem Q, Crabb JS, Mahfouz RZ, Radivoyevitch T, Crabb JW, Saunthararajah Y.

J Biol Chem. 2014 May 23;289(21):14881-95. doi: 10.1074/jbc.M114.562447. Epub 2014 Apr 2.

44.

Aging effects on oxidative phosphorylation in rat adrenocortical mitochondria.

Solinas P, Fujioka H, Radivoyevitch T, Tandler B, Hoppel CL.

Mech Ageing Dev. 2014 Jun;138:10-4. doi: 10.1016/j.mad.2014.01.009. Epub 2014 Jan 31.

PMID:
24486556
45.

Sex differences in the incidence of chronic myeloid leukemia.

Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, Gale RP, Sachs RK.

Radiat Environ Biophys. 2014 Mar;53(1):55-63. doi: 10.1007/s00411-013-0507-4. Epub 2013 Dec 13.

46.

Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials.

Radivoyevitch T, Saunthararajah Y.

J Clin Oncol. 2014 Jan 1;32(1):60-1. doi: 10.1200/JCO.2013.52.5980. Epub 2013 Nov 18. No abstract available.

PMID:
24248691
47.

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, Fusco N, Adams R, Redline R, Faulhaber P, Dowlati A.

Gynecol Oncol. 2013 Jul;130(1):75-80. doi: 10.1016/j.ygyno.2013.04.019. Epub 2013 Apr 18.

48.

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y.

Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3.

49.

dNTP Supply Gene Expression Patterns after P53 Loss.

Radivoyevitch T, Saunthararajah Y, Pink J, Ferris G, Lent I, Jackson M, Junk D, Kunos CA.

Cancers (Basel). 2012 Nov 20;4(4):1212-24. doi: 10.3390/cancers4041212.

50.

Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.

Kunos CA, Radivoyevitch T, Kresak A, Dawson D, Jacobberger J, Yang B, Abdul-Karim FW.

Int J Gynecol Cancer. 2012 Nov;22(9):1463-9. doi: 10.1097/IGC.0b013e318270577f.

Supplemental Content

Loading ...
Support Center